http://rdf.ncbi.nlm.nih.gov/pubchem/patent/RU-2266757-C2
Outgoing Links
| Predicate | Object |
|---|---|
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K36-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61M15-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61N7-00 |
| filingDate | 2003-07-14-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2005-12-27-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_f0e070f1a0b5905d9067cb5d82144d99 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_45c6d71cccfeae1cc18c4a77311f1620 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_d7364e2f23ad49e5d5624ed8275ee795 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_fdfc1e806b4b7554a035cf7f7541fa0c http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_ace9579a61791d07e8a3b6268e5b5e2d http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_571077db9a528fa7340c286e53fdfc4a http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_c3b25e4fa943576c86755b0827b2893a http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_0d813e439eee052a93441ca1ec7aa847 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_a7a268221e5a9fb5436b6fb82be409ba http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_a7fa1e54de1790e1b6094a1ef6b7ca7d http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_5371f2ffcc8e6b5843f40ecfd5f117f9 |
| publicationDate | 2005-12-27-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | RU-2266757-C2 |
| titleOfInvention | Method for suppressing atypical pneumonia coronavirus |
| abstract | FIELD: medicine. n SUBSTANCE: method involves administering ultrasonic ozonide-containing drug aerosol inhalation as ozonized oil and water mixture. Ultrasonic inhalation is additionally applied to bronchopulmonary system using highly refined aerosol containing ozonized oil having ozonide-based peroxide number P=800-900 and aerosol particle diameter equal to 0.3-0.5 mcm, giving at least two sessions per day at pathologic process active phase stage. Bronchopulmonary system tissue edema being relieved, ultrasonic inhalation procedure is first applied using highly refined aerosol containing ozonized oil having 20% ozonized oil emulsion of oil-in-water type having peroxide number P=200 and aerosol particle diameter equal to 0.3-0.5 mcm, giving at least two sessions per day at infection regeneration stage until clinically proved patient recovery data being obtained. Next, ultrasonic inhalation procedure is applied using medium refined aerosol containing ozonized oil having peroxide number P=800-900 and aerosol particle diameter equal to 5.0-10.0 mcm, each inhalation procedure being at least 10 min long. n EFFECT: enhanced effectiveness of treatment. n 2 cl, 1 dwg |
| isCitedBy | http://rdf.ncbi.nlm.nih.gov/pubchem/patent/RU-2791808-C2 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/RU-2725980-C1 |
| priorityDate | 2003-07-14-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 36.